$HOWL

Werewolf Therapeutics, Inc.

Werewolf Therapeutics develops engineered medicines designed to stimulate the immune system to treat cancer and other immune-mediated conditions. Its PREDATOR platform produces conditionally activated INDUKINE molecules, which are designed to release immune-modulating cytokines in the tumor microenvironment, and INDUCER molecules, which are T cell engagers designed to activate selectively in tumors. The pipeline includes clinical-stage WTX-124 and WTX-330, preclinical candidates for cancer and inflammatory diseases, and WTX-1011 and WTX-2022, which target tumor-associated antigens. Werewolf has licensed worldwide development and commercialization rights to JZP898, an IFNα INDUKINE molecule, to Jazz Pharmaceuticals Ireland Limited. The company develops its own product candidates and earns money through licensing and collaboration arrangements. Werewolf Therapeutics is headquartered in Waltham, Massachusetts.

AlphAI earnings readsecond quarter of 2026 · JUL 31Werewolf Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate UpdatesVerdict: mixed

Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.

No enriched coverage for $HOWL in the last 7 days.

No SEC Form 4 filings for $HOWL in the last 30 days.

See all $HOWL insider activity →
Med

Werewolf Therapeutics’ Clinical Data for WTX-124 and WTX-330 Presented at the Society for Immunotherapy of Cancer’s (SITC) 2026 Annual Meeting

Werewolf Therapeutics, Inc. (HOWL) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Werewolf Therapeutics’ Clinical Data for WTX-124 and WTX-330 Presented at the Society for Immunotherapy of Cancer’s (SITC) 2026 Annual Meeting – In a Phase 1/1b clinical trial , WTX-124 was administered safely at its recommended Phase 2 dose of 18 mg IV Q2W in the ou

Werewolf Therapeutics reports clinical trial data for cancer drugs

Werewolf Therapeutics (NASDAQ:HOWL) presented clinical trial data for two cancer drugs at a conference. WTX-124 showed responses in solid tumors, with a 37.5% response rate in lung cancer when combined with pembrolizumab. WTX-330 showed a partial response in gallbladder cancer. The FDA agreed on a Phase 2 dose for WTX-124. Data was current as of mid-2026.

HOWL sentiment & insider activity

Recent HOWL coverage spans mergers & acquisitions, corporate actions and technology.

What's driving HOWL

AlphAI scores every news story that mentions HOWL with an AI model for sentiment and relevance, and aggregates insider trades from Werewolf Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $HOWL

Score
$HOWLMedAI 8/10Clinical / regulatory· topline data

Werewolf Therapeutics’ Clinical Data for WTX-124 and WTX-330 Presented at the Society for Immunotherapy of Cancer’s (SITC) 2026 Annual Meeting

Werewolf Therapeutics, Inc. (HOWL) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Werewolf Therapeutics’ Clinical Data for WTX-124 and WTX-330 Presented at the Society for Immunotherapy of Cancer’s (SITC) 2026 Annual Meeting – In a Phase 1/1b clinical trial , WTX-124 was administered safely at its recommended Phase 2 dose of 18 mg IV Q2W in the ou

$HOWLHighAI 8/10

Werewolf Therapeutics And Ambros Therapeutics Announce Merger; Secure $150M Financing

Werewolf Therapeutics (HOWL) and Ambros Therapeutics announced an all-stock merger, creating a Nasdaq-listed biotech firm focused on neridronate for CRPS-1. The combined company, trading as AMBX, secured $150M in financing. Neridronate has FDA designations and is in Phase 3 trials, with results expected in 2028. The merger values Ambros at $500M and Werewolf at $47.5M, with a planned Q1 2027 close. HOWL shares surged 1431.19% in pre-market trading.

$HOWLHighM&A· acquirer · $500M · definitive

Werewolf Therapeutics, Inc. (HOWL): Entry into a Material Definitive Agreement

Werewolf Therapeutics, Inc. (HOWL) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Werewolf Therapeutics and Ambros Therapeutics Announce Merger Agreement and Concurrent Oversubscribed $150 million Private Placement • Proposed merger to create a Nasdaq-listed, late-stage biotechnology company advancing neridronate, a potential first FDA-approved tr

After-hours Gainers: HOWL Jumps 90%, MODD To Begin Pivot Pump Rollout, BIVI Awaits Long COVID Data

Werewolf Therapeutics (HOWL) rose 90% in after-hours trading, with key clinical trials ongoing. GeoVax (GOVX) gained 12.66%, preparing for a pivotal Phase 3 study. Greenwich LifeSciences (GLSI) increased 6.27%, extending share lock-up. Modular Medical (MODD) up 7.87%, planning Pivot pump rollout. Ovid Therapeutics (OVID) rose 6.93%, with multiple clinical milestones. BioVie (BIVI) up 4.84%, awaiting long COVID data.

$HOWLMedM&A· $28M · definitive

Werewolf Therapeutics, Inc. (HOWL): Entry into a Material Definitive Agreement

Werewolf Therapeutics, Inc. (HOWL) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01. Entry into a Material Definitive Agreement. On August 14, 2026 (the “Closing”), Werewolf Therapeutics, Inc. (the “Company”) entered into an asset purchase agreement (the “Purchase Agreement”) with EMD Serono Research & Development Institute Inc. (“EMD”), pursuant to wh

Related tickers